Q1 2018 results and outlook

Webcast 4 May 2018





Today's agenda

- Q1 2018
- Update on business priorities
- Outlook for 2018
- Q&A session



President & CEO Carsten Hellmann EVP, Group CFO Søren Jelert




VP, Head of IR Per Plotnikof

This presentation contains forward-looking statements, including forecasts of future revenue and operating profit, as well as expected business-related events. Such statements are subject to risks and uncertainties as various factors, some of which are beyond ALK's control, may cause actual results and performance to differ materially from the forecasts made in this presentation.

Q1 2018 highlights

- Good progress with new growth strategy on all four pillars
- Financially better than expected, mainly due to faster capture of efficiencies and savings
- EBITDA of DKK 92 million (140)
- Improved 2018 outlook



Europe: Strong growth in tablets

Growth rates are stated as growth in local currencies

- Revenue: DKK 601m (616m)
- Now >125,000 people on ACARIZAX[®] and GRAZAX[®]
 - Strong ACARIZAX[®] launch in France
- SCIT/SLIT-drops still affected by previous capacity constraints and portfolio pruning
- No significant changes to price/ reimbursement in Q1









North America & Int'l markets

Growth rates are stated as growth in local currencies

North America

- Revenue: DKK 131m (152m)
- -2% growth (local cur.) -12 pp currency impact
- Tablets: Patient uptake as planned but fluctuations at wholesaler levels
- SCIT up 14%
- Other products down 12%

Int'l markets

- Revenue: DKK 20m (21m)
- 2% growth in local currencies (phasing)
- Increasing contribution from Japan
- Fluctuating shipments into China



Revenue in North America



Q1 2018 results

DKK million	Q1 2017	Q1 2018
Revenue	789	752
Gross profit	489	440
Gross margin	62%	59%
Capacity costs	393	393
EBIT	96	47
Financials, net	(8)	(21)
Тах	86	2
Net profit	2	24
EBITDA	140	92
Free cash flow	(206)	(75)

Flat despite continued S&M investments

> Cash ~**DKK 619m**

New credit facility **DKK 600m**



Progress on strategic priorities

ACARIZAX 12 SQ-HDM

Lyophilisat zum Einnehmen andardisierter Allergenextrakt aus Hausstr atophagoides pteronyssinus und atophagoides farinae

ACARIZAX

12 SQ-HDM Lyophilisat zum Einnehr

2.

Complete the clinical development of the tablet The starting point: AIT leadership - SLIT-tablets, SLIT-drops, SCIT and related products

3.

Build patient engagement and adjacencies to reach remaining 99% of people with allergy

Optimise and reallocate resources to focus on the new strategy and achieve efficiencies

1.

Succeed in North

America with own

direct sales

organisation

Succeed in North America

- Still early days, but encouraging feedback and patient uptake
- Prescriber network
 - ~400 / 2,000 active in the USA
 - ~110 / 150 active in Canada
- Q1: 1,200-1,300 patients initiated on treatment with ODACTRA™ in the USA
 - Similar number in Canada
- Good progress with insurance coverage

8







Strategic priority No 2



Complete the tablet portfolio for all relevant ages

- All clinical activities on track
- ACARIZAX[®]
 - Approved for use in children in Japan
 - Asthma trial recruiting patients in EU
- CEDARCURE[™] launch in Japan soon
- Regulatory filing of tree SLIT-tablet in Europe expected soon



ALK is committed to globalising a full portfolio of SLITtablets for all relevant ages – adults, adolescents and children – covering the five most common global respiratory allergies



Patient engagement and adjacencies

 The first version of new consumer care platform and products launched in Germany (klarify.me)



• Launch of consumer care and digital engagement in other markets later in 2018



klarify

- Partnership on allergen diagnosis technology in China
- Ongoing work to source additional products and establish further adjacencies

ALK will drive digital patient engagement with the ultimative aim of supporting people with allergy earlier in their disease journey and creating new value from ALK's expanded allergy presence



Optimise and reallocate resources

- SCIT and SLIT-drop production in Denmark and France stabilised and output on track
- Global inventories on track to normalise during 2018
- Efforts to prune portfolio and improve efficiency, quality and compliance are ahead of plan



ALK will improve efficiency by strengthening its competencies and structures as well as simplifying processes, particularly within product supply

2018 outlook adjusted slighty upwards

DKK	2018E	2018E (previous)	Comments	2017A
Revenue	>2.7bn	~2.7bn	Slightly improved outlook due to performance in Q1. Still strong growth in tablet sales offset by product eliminations, effect of previous supply constraints and price/reimbursement pressure. Negative currency effect.	2.9bn
EBITDA	~0	~(50)m	Improved outlook due to better than expected performance in Q1. Still significant business investments to transform ALK	253m
Free cash flow	(600)m or better	~(600)m	Slightly improved outlook due to Q1 performance. Still influenced by subdued earnings, working capital requirements and CAPEX investments	(745)m



Q&A Session

Q1 2018 results & outlook - Webcast - 4 May 2018 13

ALK

Thank you for your attention

Upcoming events:

7 May: Roadshow Copenhagen8 May: Roadshow London9 May: Roadshow Amterdam

Investor Relations: Per Plotnikof, VP, Head of Investor Relations Phone: +45 4574 7576 E-mail: ppidk@alk.net Read more: www.alk.net